Collplant Biotechnologies Ltd

NASDAQ:CLGNUnited States

Nov 27, 2024

Show headlines and story abstract

• DJ Collplant Biotechnologies Is Maintained at Buy by D. Boral Capital, from 8:57AM ET on Wednesday Nov 27, 2024 by Dow Jones

  8:57AM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: CLGN
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CLGN/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 27, 2024 08:57 ET (13:57 GMT)
  

• -- Earnings Flash (CLGN) COLLPLANT Posts Q3 Revenue $4,000, from 7:01AM ET on Wednesday Nov 27, 2024 by MT Newswires

  7:01AM ET on Wednesday Nov 27, 2024 by MT Newswires
  Companies Mentioned: CLGN
  07:01 AM EST, 11/27/2024 (MT Newswires) -- ...

• COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE, from 7:00AM ET on Wednesday Nov 27, 2024 by PR Newswire

  7:00AM ET on Wednesday Nov 27, 2024 by PR Newswire
  Companies Mentioned: CLGN

  Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue

• COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE, from 7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones

  7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: CLGN
  
  its next large-animal study for its breast implants in a timely manner, or at all; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel, projected capital expenditures and liquidity, changes in the Company's strategy and development plans and projects,, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.